In an adequately powered, randomized controlled trial conducted over 2 years, the desired clinical outcome (i.e. prevention of a serious cardiovascular event) with a new drug is achieved in 25% of the study sample. In the patients who receive a placebo, only 15% obtain the same clinical benefit. The relative risk reduction achieved with the new drug over the study period is:
Tambra
1 months agoOzell
2 days agoMarg
4 days agoAltha
2 months agoJamal
2 months agoPamella
16 days agoXenia
21 days agoSkye
1 months agoDeonna
1 months agoElvis
2 months agoDenise
22 days agoJaclyn
25 days agoTimothy
1 months agoYuonne
2 months agoMalcolm
26 days agoKizzy
1 months agoAndrew
1 months agoOmega
1 months agoThea
2 months agoMelynda
2 months agoEllen
3 months agoDaren
3 months agoRuth
3 months ago